Tag: Hydroxychloroquine

India Treats Medical Staff Prophylactically and Early, and It Makes a Difference – The Chloroquine Wars Part XXXI

During the first wave, the primary antiviral used was HCQ, and during the second wave (after Facebook censored his account where he was communicating with others in a large nation) they shifted to ivermectin due to HCQ controversies. Similarly to the way Dr. Brian Tyson attacked COVID-19 with an early multi-drug regimen, numerous other medicines, including aspirin, were used. Of Dr. Shah’s 8,000 or so patients, only 5 succumbed to COVID-19. This is notably similar to the results of Dr. Didier Raoult.

Read More »

Institutional Funding of Propaganda Against Early Treatment of COVID-19 – The Chloroquine Wars Part XXX

This is pulled straight from the same playbook as the propaganda against HCQ. Even if you’re not sure that one or both of these medicines is effective despite uniformly positive results when applied as early treatment, you should at least recognize the pattern, scratch your head, and question whether there is…maybe…just possibly some perverse incentive like power or profit from vaccines driving this absurdity.

Read More »

New study reveals success of hydroxychloroquine as COVID treatment

In a new study, Smith and three other medical experts prove what he and this show have been telling you for more than a year that hydroxychloroquine can save lives. Smith’s landmark study followed 255 COVID patients who required intubation during the first two months of the pandemic, and it found that increased doses of coadministered, hydroxychloroquine and azithromycin were associated with a greater than 100% increase in survival.

Read More »

HYDROXYCHLOROQUINE – Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic

Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.

Read More »

Is the vaccine safe? Undoing the spin on the vaccine. We have safe and effective treatment options for COVID.

Doctors have found safe, effective and inexpensive treatments that work well in preventing and treating patients with COVID-19 like Ivermectin that’s been used safely for more than 30 years.
But the government has not supported the use of this effective drug. In fact, there are other therapies like hydroxychloroquine, vitamins D and C and zinc that physicians have found to be safe and effective in preventing and treating COVID.

Read More »

An Interview with Dr Vladimir Zelenko, MD

We are very honored to present this interview of Dr Vladimir Zelenko, the father of outpatient treatment for COVID-19 in North America. Dr Zelenko shares his own experience with COVID-19 as a patient, as he is recovering from a severe form of the disease.
He also talks about his cancer and how he was able to go through this dramatic episode of his life. Then, he presents his perspectives about outpatient treatment as practiced today and the evolution of the pandemic, among other topics.

Read More »

The Chloroquine Wars Part XVII – Why the Story About India’s April COVID-19 Spike is All Wrong

So, what’s different between Maharashtra and Delhi with respect to the rest of India and South Asia? Instead of relying on HCQ and IVM, many doctors and health officials in Maharashtra and Delhi pushed the expensive and profitable remdesivir drug. Due to its cost and recommended time of usage, remdesivir is not used either as a prophylaxis or for early outpatient treatment. And unlike the cheap and easy-to-produce HCQ and IVM, remdesivir is difficult to replace when it runs out.

Read More »

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »

Doctor’s Advice on Early Treatment for COVID-19

Every viral illness starts that way. The more it’s allowed to progress, the more it takes over the cells and replicates itself. That’s why this virus absolutely had to be treated early to prevent those damages. Primarily what has killed people with COVID is a delay to treatment, and allowing the exaggerating inflammatory response and blood clotting response to take hold in the body.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

Read More »